Hemophilia B (Factor IX Deficiency) - Pipeline Review, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H2 2020, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B (Factor IX Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 10, 7, 2, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively.
Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H2 2020, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape.
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include bleeding into joints and associated pain and swelling, bruising, excessive bleeding following circumcision, gastrointestinal tract and urinary tract hemorrhage and nosebleeds. Treatment includes replacing the defective clotting factor.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia B - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hemophilia B (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia B (Factor IX Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 10, 7, 2, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively.
Hemophilia B (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia B (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hemophilia B (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemophilia B (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemophilia B (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia B (Hematological Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemophilia B (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemophilia B (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Hemophilia B (Factor IX Deficiency) - Overview
Hemophilia B (Factor IX Deficiency) - Therapeutics Development
Hemophilia B (Factor IX Deficiency) - Therapeutics Assessment
Hemophilia B (Factor IX Deficiency) - Companies Involved in Therapeutics Development
Hemophilia B (Factor IX Deficiency) - Drug Profiles
Hemophilia B (Factor IX Deficiency) - Dormant Projects
Hemophilia B (Factor IX Deficiency) - Discontinued Products
Hemophilia B (Factor IX Deficiency) - Product Development Milestones
Appendix
Hemophilia B (Factor IX Deficiency) - Overview
Hemophilia B (Factor IX Deficiency) - Therapeutics Development
Hemophilia B (Factor IX Deficiency) - Therapeutics Assessment
Hemophilia B (Factor IX Deficiency) - Companies Involved in Therapeutics Development
Hemophilia B (Factor IX Deficiency) - Drug Profiles
Hemophilia B (Factor IX Deficiency) - Dormant Projects
Hemophilia B (Factor IX Deficiency) - Discontinued Products
Hemophilia B (Factor IX Deficiency) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Hemophilia B (Factor IX Deficiency), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by ApcinteX Ltd, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by ASC Therapeutics Inc, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Catalyst Biosciences Inc, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Expression Therapeutics LLC, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Freeline Therapeutics Ltd, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by GC Pharma, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Genzyme Corp, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Intellia Therapeutics Inc, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by LFB SA, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Logicbio Therapeutics Inc, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Novo Nordisk AS, H2 2020
Hemophilia B (Factor IX Deficiency) - Dormant Projects, H2 2020
Hemophilia B (Factor IX Deficiency) - Discontinued Products, H2 2020
Number of Products under Development for Hemophilia B (Factor IX Deficiency), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by ApcinteX Ltd, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by ASC Therapeutics Inc, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Catalyst Biosciences Inc, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Expression Therapeutics LLC, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Freeline Therapeutics Ltd, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by GC Pharma, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Genzyme Corp, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Intellia Therapeutics Inc, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by LFB SA, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Logicbio Therapeutics Inc, H2 2020
Hemophilia B (Factor IX Deficiency) - Pipeline by Novo Nordisk AS, H2 2020
Hemophilia B (Factor IX Deficiency) - Dormant Projects, H2 2020
Hemophilia B (Factor IX Deficiency) - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Hemophilia B (Factor IX Deficiency), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
ApcinteX Ltd
ASC Therapeutics Inc
Catalyst Biosciences Inc
Chengdu Rongsheng Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Expression Therapeutics LLC
Freeline Therapeutics Ltd
GC Pharma
Genzyme Corp
Intellia Therapeutics Inc
LFB SA
Logicbio Therapeutics Inc
Novo Nordisk AS
OPKO Health Inc
Pfizer Inc
RegenxBio Inc
Sangamo Therapeutics Inc
Sanofi
Shenzhen Weiwu Guangming Biological Preparations Co Ltd
Sigilon Therapeutics Inc
Staidson BioPharma Inc
Takeda Pharmaceutical Co Ltd
UBI Pharma Inc
UniQure NV
Number of Products under Development for Hemophilia B (Factor IX Deficiency), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
ApcinteX Ltd
ASC Therapeutics Inc
Catalyst Biosciences Inc
Chengdu Rongsheng Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Expression Therapeutics LLC
Freeline Therapeutics Ltd
GC Pharma
Genzyme Corp
Intellia Therapeutics Inc
LFB SA
Logicbio Therapeutics Inc
Novo Nordisk AS
OPKO Health Inc
Pfizer Inc
RegenxBio Inc
Sangamo Therapeutics Inc
Sanofi
Shenzhen Weiwu Guangming Biological Preparations Co Ltd
Sigilon Therapeutics Inc
Staidson BioPharma Inc
Takeda Pharmaceutical Co Ltd
UBI Pharma Inc
UniQure NV
